Watch Cleo’s Head of Corporate Development, Dayna Louca’s Q&A on the JMM Expert Insights Series

Media
Written By Andrew ZAPPIA

Cleo’s Chief Scientific Officer Dr Andrew Stephens and Head of Corporate Development Dayna Louca recently spoke at the JMM Opera House Investor Lunch on how their breakthrough CXCL10 biomarker platform could address one of medicine’s toughest challenges, the early detection of ovarian cancer.

Watch the Q&A with Head of Corporate Development Dayna Louca.

Andrew ZAPPIA
Next

CLEO Continues on Pathway for U.S. Regulatory Approval with Positive FDA Feedback